Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.
Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.
Center for Integrated Protein Science Munich (CIPSM); Division of Clinical Pharmacology; Department of Internal Medicine; Ludwig-Maximilian University of Munich; Munich, Germany ; Department of Medicine; University of Fribourg; Fribourg, Switzerland.
Christian
C
Hotz
Carole
C
Bourquin